

Attorney Docket No.: 5565.214-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Woldike et al.

Serial No.: 10/044,426

Group Art Unit: 1636

Filed: November 13, 2001

Examiner: Maria Marvich

Confirmation No: 3262

For: Method For The Production Of FVII

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Petition and Fee for Extension of Time – 3 months (in duplicate)
2. Amendment
3. Notice of Appeal (in duplicate)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
Washington, DC 20231

on February 21, 2003.

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900
PATENT



Attorney Docket No.: 5565.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Woldike et al.

Application No.: 10/044,426

Group Art Unit: 1636

Filed: November 13, 2001

Examiner: M. Marvich

For: Method for the Production of FVII

AMENDMENT UNDER 37 C.F.R. 1.116

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed August 28, 2002, kindly amend the above-identified application as set forth below.

IN THE CLAIMS:

Cancel claims 2 and 3 without prejudice or disclaimer.

Substitute the following claims for claims having the same number.

1. (Twice amended) A method for producing Factor VII comprising (a) cultivation of a mammalian cell line comprising a DNA sequence encoding a Kex2 variant having Kex2 enzymatic activity and a DNA sequence encoding Factor VII (FVII) in a suitable culture medium, under conditions in which both said endoprotease and said FVII are expressed; and (b) isolation of Factor VII from the medium.

4. (Amended) The method of claim 3 wherein the Kex2 variant is C-terminally truncated Kex2 and has no transmembrane region.

5. (Amended) The method of claim 4, wherein the Kex2 variant has an ER retention signal added to the C-terminal end.

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900
#13/C NE
Yuta
3/7/03

Do not enter
MM
3/25/03

C1

C2